Table 2.
Adherence by severity of airflow limitation (unadjusted)
| Medication | FEV1 ≥ 80% |
50% ≤ FEV1 < 80% |
30% ≤ FEV1 < 50% |
FEV1 < 30% |
||||
|---|---|---|---|---|---|---|---|---|
| n | % Adherent | n | % Adherent | n | % Adherent | n | % Adherent | |
| Antihypertensives | ||||||||
| β-Blockers | 1,592 | 50.4% | 2,818 | 54.5% | 938 | 50.0% | 234 | 45.7% |
| Calcium channel blockers | 869 | 52.8% | 1,632 | 55.1% | 592 | 48.0% | 176 | 44.9% |
| Thiazides | 1,159 | 48.0% | 1,777 | 46.9% | 547 | 43.0% | 158 | 45.6% |
| ACEIs | 1,621 | 54.7% | 2,775 | 53.6% | 939 | 52.1% | 265 | 47.5% |
| Diabetes medications | ||||||||
| Sulfonylureas | 453 | 51.9% | 911 | 54.1% | 296 | 49.3% | 73 | 42.5% |
| Metformin | 471 | 50.5% | 848 | 48.9% | 209 | 45.0% | 54 | 42.6% |
Definition of abbreviation: ACEIs = angiotensin-converting enzyme inhibitors.